Skip to content
Research archive

Research Articles

Research Article

Comparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study).

Synthetic Semaglutide Matches Innovator Wegovy for Weight Loss in Indian Adults — A phase III randomised trial in Indian adults with obesity found that a synthetic semaglutide formulation produced nearly identical weight loss to innovator semaglutide (Wegovy®) over 24 weeks, with a least square-mean difference of just 0.

Mar 29, 2026 · Cureus · Metabolism
86
Research Article

Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial.

Pimicotinib Achieves 54% Response Rate in Unresectable TGCT Phase 3 Trial — In a randomised, placebo-controlled phase 3 trial, pimicotinib produced an objective response rate of 54% compared with 3% for placebo in patients with unresectable, symptomatic tenosynovial giant cell tumour — an absolute difference of 51 percentage points (95% CI 33–63, p<0.

Mar 28, 2026 · Lancet · Oncology
86
Clinical Trial

Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.

Oral Orforglipron Achieves Superior Weight Reduction Versus Placebo in Diabetic Obesity — Once-daily oral orforglipron produced statistically superior bodyweight reduction compared with placebo over 72 weeks in adults with obesity or overweight and type 2 diabetes, across all three doses tested in this large phase 3 trial.

Mar 28, 2026 · Lancet · Metabolism
88
Research Article

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer’s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.

Oral Semaglutide Fails to Slow Clinical Progression in Early Alzheimer's Disease — In two large phase 3 placebo-controlled trials, oral semaglutide 14 mg produced no meaningful reduction in cognitive and functional decline in early Alzheimer's disease — the estimated difference in CDR-SB score change was negligible and statistically indistinguishable from zero in both evoke (−0.

Mar 28, 2026 · Lancet · Metabolism
93
Randomized Controlled Trial

Pharmacological and metabolic effects of Bifidobacterium tri

Traditional Exercise Shows Greater Glucose Reductions Than Aerobic Exercise in Pilot Trial — Huatuo Five-animal Play exercise produced significantly greater reductions in fasting blood glucose, post-load glucose, insulin resistance, and Wnt5a signaling compared to low-intensity aerobic exercise in patients with impaired glucose tolerance (P

Mar 26, 2026 · Pak J Pharm Sci · Metabolism
62
Meta-Analysis

Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin.

NOACs Significantly Reduce Systemic Embolic Events Versus Warfarin in Atrial Fibrillation — In a large individual patient data meta-analysis of 71,683 participants, non-vitamin K antagonist oral anticoagulants (NOACs) significantly reduced the risk of systemic embolic events (SEEs) compared with warfarin in patients with atrial fibrillation.

Mar 25, 2026 · Circulation · Cardiology
68
Meta-Analysis

Comparative effectiveness of percutaneous coronary intervention strategies for coronary small-vessel disease: a network meta-analysis of randomized trials.

Sirolimus-Eluting Stents Rank Highest Across Outcomes in Coronary Small-Vessel PCI — Across 39 randomized trials enrolling more than 14,500 patients, sirolimus-eluting stents (SES) consistently ranked first for reducing target lesion revascularization, binary restenosis, and myocardial infarction in coronary small-vessel disease, cutting TLR risk by about 75% compared with bare-metal stents (OR 0.

Mar 25, 2026 · Ann Med · Cardiology
76
Meta-Analysis

Comparison of Fasting and Nonfasting Regimens Outcomes Before Catheterization Laboratory Procedures: A Systematic Review and Meta-Analysis.

Nonfasting Before Cath Lab Procedures Shows No Worse Safety Outcomes Than Fasting — A meta-analysis of eight randomized controlled trials found no statistically significant differences between fasting and nonfasting patients across five key safety outcomes — including aspiration pneumonia, hypoglycemia, and mortality — before catheterization laboratory procedures.

Mar 24, 2026 · Crit Pathw Cardiol · Cardiology
66